Oral Iron (Ferrous sulphate)

DRUG2 trials

Sponsors

Vifor Pharma, University of Aarhus

Conditions

AnemiaChronic Kidney DiseaseHip FractureIronIron Deficiency AnaemiaPlacebo - Control

Phase 3

Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

CompletedNCT00994318

Vifor PharmaChronic Kidney Disease, Iron Deficiency Anaemia

Start: 2009-12-31End: 2014-02-28Updated: 2014-05-20

Phase 4

IRONCARE: Iron Treatment in Older Patients With Hip Fractures

Not yet recruitingNCT07659184

University of AarhusAnemia, Hip Fracture, Iron +1

Start: 2026-10-01End: 2028-09-30Target: 528Updated: 2026-06-24

Related Papers

Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial.

2017-09-0132 citations

Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial.

2017-01-1712 citations

FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia

Nephrology Dialysis Transplantation2014-06-02320 citations

The FIND-CKD study--a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale.

2013-10-2930 citations